We have located links that may give you full text access.
Topical treatment with the bacterium-derived c-Met agonist InlB 321 /15 accelerates healing in the abrasion wound mouse model.
Archives of Dermatological Research 2018 October 11
Studies of factors affecting wound-healing rates are encouraged by a critical need for new treatments to manage an increasing burden of non-healing wounds. The InlB protein produced by the Gram-positive bacterium Listeria monocytogenes is an agonist of the tyrosine kinase receptor c-Met and a functional analog of the hepatocyte growth factor (HGF), which is a mammalian ligand of c-Met. The recombinant InlB321 protein, which is the c-Met-binding InlB domain (amino acids 31-321), was cloned from the L. monocytogenes serovar 4b clinical strain VIMHA015 and serovar 1/2a strain EGDe (InlB321 /15 and InlB321 /EGDe, respectively). Both InlB321 variants stimulated proliferation of endothelial HUVEC cells. InlB321 /15 was more active in Erk1/2 phosphorylation assay, and more potent than InlB321 /EGDe in the 2D-scratch wound-healing assay. Scratch closure reached 86%, 29% and 72% for InlB321 /15, InlB321 /EGDe and HGF, respectively, 72 h post-wounding (p < 0.05). Topically applied glycerol-mixed InlB321 /15 (300 µg ml- 1 ) increased abrasion wound-healing rates in mice. The 50% wound closing time (CT50) was reduced by InlB321 /15 (4.18 ± 0.91 days; CI: 3.05; 5.31) compared with control animals (5.51 ± 1.21 days; CI: 4.01; 7.01; p < 0.05). Taken together, obtained results suggested a potential of InlB321 /15 as a means of accelerating wound healing.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app